Therefore, our findings suggest a novel therapeutic strategy that combines treatments targeting both YKL-40 and VE-cad/or PD-L1 facilitates the blockade of anti-vascular immune evasion and tumor angiogenesis, benefiting patients with mesenchymal GBM. The gene discussed is CHI3L1; the disease is glioblastoma.